Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

NCT07195617 is registered in ClinicalTrials.gov with Guangzhou Bio-gene Technology Co., Ltd as lead sponsor.

NCT NCT07195617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07195617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Phase
Not applicable
Overall status
Withdrawn
Start date
October 10, 2025
Completion date
November 1, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma